Literature DB >> 25921580

Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy.

Yang Zhang1, Kun Ling Ma2, Jing Liu1, Yu Wu1, Ze Bo Hu1, Liang Liu1, Bi Cheng Liu1.   

Abstract

Dyslipidemia plays crucial roles in the progression of diabetic nephropathy (DN). This study investigated the effects of high glucose on lipid accumulation in podocytes and explored its underlying mechanisms. Male db/m and db/db mice were fed a normal chow diet for 8 wk. Immortalised mouse podocytes were treated with or without high glucose for 24 h. The changes to the morphology and ultramicrostructures of the kidneys in mice were examined using pathological staining and electron microscopy. Intracellular lipid accumulation was evaluated by Oil Red O staining and a free cholesterol quantitative assay. The expressions of the molecules involved in low-density lipoprotein receptor (LDLr) pathway and podocyte injury were examined using immunofluorescent staining, real-time PCR, and Western blot. There were increased levels of plasma lipid, serum creatinine, and proteinuria in db/db mice compared with db/m mice. Moreover, there was significant mesangial matrix expansion, basement membrane thickening, podocyte foot process effacement, and phenotypic alteration in the db/db group. Additionally, lipid accumulation in the kidneys of db/db mice was increased due to increased protein expressions of LDLr, sterol regulatory element-binding protein (SREBP) cleavage-activating protein, and SREBP-2. These effects were further confirmed by in vitro studies. Interestingly, the treatment with LDLr siRNA inhibited lipid accumulation in podocytes and decreased the protein expression of molecules associated with phenotypic alteration in podocytes. High glucose disrupted LDLr feedback regulation in podocytes, which may cause intracellular lipid accumulation and alteration of podocyte phenotype, thereby accelerating DN progression.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  diabetic nephropathy; low-density lipoprotein receptor; podocyte

Mesh:

Substances:

Year:  2015        PMID: 25921580     DOI: 10.1152/ajpendo.00591.2014

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  16 in total

1.  Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation.

Authors:  Bin Zhang; Xuelian Zhang; Chenyang Zhang; Guibo Sun; Xiaobo Sun
Journal:  Pharm Res       Date:  2021-11-12       Impact factor: 4.200

2.  Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease.

Authors:  Ying Shao; Huiwen Ren; Chuan Lv; Xiaoyu Ma; Can Wu; Qiuyue Wang
Journal:  Endocrine       Date:  2016-08-13       Impact factor: 3.633

Review 3.  Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.

Authors:  Vivette D D'Agati; Avry Chagnac; Aiko P J de Vries; Moshe Levi; Esteban Porrini; Michal Herman-Edelstein; Manuel Praga
Journal:  Nat Rev Nephrol       Date:  2016-06-06       Impact factor: 28.314

4.  The unique molecular mechanism of diabetic nephropathy: a bioinformatics analysis of over 250 microarray datasets.

Authors:  Le-Ting Zhou; Zhi-Jian Zhang; Jing-Yuan Cao; Hanzhi Chen; Yu-Shan Zhu; Xi Wu; Abdul Qadir Nawabi; Xiaobin Liu; Weiwei Shan; Yue Zhang; Xi-Ran Zhang; Jing Xue; Ling Hu; Si-Si Wang; Liang Wang; Zhu-Xing Sun
Journal:  Clin Kidney J       Date:  2021-03-18

Review 5.  Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury.

Authors:  Yang Zhang; Kun Ling Ma; Xiong Zhong Ruan; Bi Cheng Liu
Journal:  Int J Biol Sci       Date:  2016-03-21       Impact factor: 6.580

6.  ε2 allele and ε2-involved genotypes (ε2/ε2, ε2/ε3, and ε2/ε4) may confer the association of APOE genetic polymorphism with risks of nephropathy in type 2 diabetes: a meta-analysis.

Authors:  Jikang Shi; Zhaorui Cheng; Shuang Qiu; Heran Cui; Yulu Gu; Qian Zhao; Yaxuan Ren; He Zhang; Helin Sun; Yunkai Liu; Yong Li; Yichun Qiao; Yueyang Hu; Yawen Liu; Yi Cheng
Journal:  Lipids Health Dis       Date:  2020-06-13       Impact factor: 3.876

7.  Sirt6 deficiency aggravates angiotensin II-induced cholesterol accumulation and injury in podocytes.

Authors:  Qian Yang; Jijia Hu; Yingjie Yang; Zhaowei Chen; Jun Feng; Zijing Zhu; Huiming Wang; Dingping Yang; Wei Liang; Guohua Ding
Journal:  Theranostics       Date:  2020-06-12       Impact factor: 11.556

Review 8.  New Pandemic: Obesity and Associated Nephropathy.

Authors:  Isha Sharma; Yingjun Liao; Xiaoping Zheng; Yashpal S Kanwar
Journal:  Front Med (Lausanne)       Date:  2021-06-29

9.  FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats.

Authors:  X-M Qi; J Wang; X-X Xu; Y-Y Li; Y-G Wu
Journal:  Inflamm Res       Date:  2015-11-13       Impact factor: 4.575

Review 10.  Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease.

Authors:  G Michelle Ducasa; Alla Mitrofanova; Alessia Fornoni
Journal:  Curr Diab Rep       Date:  2019-11-21       Impact factor: 5.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.